Attached files

file filename
8-K - CURRENT REPORT - VirtualScopics, Inc.v327996_8k.htm

 

EXHIBIT 99.1

500 Linden Oaks

Rochester, New York 14625

 

VirtualScopics Reports 3rd Quarter 2012 Results

Earnings call scheduled for 11am ET today

 

ROCHESTER, NY – November 9, 2012 – VirtualScopics, Inc. (NASDAQ: VSCP), a leading provider of quantitative medical imaging, today reported revenues of $3,328,217 for the third quarter of 2012 compared to revenues of $3,268,807 in the third quarter of 2011. Gross profit for the quarter ended September 30, 2012 was $1,462,056 compared to $1,496,626 for the quarter ended September 30, 2011. Operating loss for the third quarter of 2012 was $53,293 compared to operating income of $19,559 in the third quarter of 2011. Earnings before interest, taxes, depreciation and amortization, and excluding stock compensation expense and gain (loss) from derivative financial instrument (“Adjusted EBITDA”) for the third quarter of 2012 was $192,045 compared to $341,669 in the comparable period in 2011.

 

Year to date, ending September 30, 2012, results were as follows:

·Total revenues of $10,366,236 compared to $10,780,710 for the first nine months of 2011.
·Gross profit of $4,216,907 compared to $4,917,385 in first nine months of 2011.
·Adjusted EBITDA of $347,124 compared to $1,223,846 in the comparable period in 2011.
·Working capital as of September 30, 2012 was $9,510,696 compared to $6,353,054 at December 31, 2011.

 

“In the third quarter we continued to experience the impact of the slowdown in new project awards, delays in the initiation of new studies, and the resulting impact on our top line,” said Jeff Markin, president and chief executive officer of VirtualScopics.  He stated, “While our third quarter revenues exceeded our prior year third quarter revenues, the rate of growth and the overall level of revenue are below our capability and expectation. Accordingly we have made, and will continue to make, changes to our selling and operational processes to maximize new project bookings and overall client satisfaction.” He concluded, “We are optimistic that because of our strong client relationships, the strengthening of the PPD alliance, and our industry reputation, this slowdown will be temporary and we anticipate returning to our historical growth rates.”

 

“In light of the softness in our revenues during 2012, we are continuing to actively monitor our level of necessary expenditures,” stated Molly Henderson, chief business and financial officer of VirtualScopics. She added, “We believe the softness in the level of new project awards will improve and, therefore, anticipate continuing to make the important investments in market opportunities that will support our long-term strategic growth.” She continued, “This includes our efforts in the field of personalized medicine which we are continuing to advance.” She concluded, “We have a significant amount of projects awaiting decisions and anticipate that we will receive word on these projects prior to the end of this year, thereby, giving us confidence as we enter 2013.”

 

-1-
 

 

Jeff Markin and Molly Henderson will provide a business and third quarter 2012 financial update during the conference call this morning at 11:00 a.m. ET. Interested participants should dial 877.407.8035 when calling within the United States or +1 201 689 8035 when calling internationally. This call can also be accessed at www.virtualscopics.com and will be available for 30 days after the call.

 

The Company provides Adjusted EBITDA as a supplemental measure to GAAP regarding the Company's operational performance. The Company defines Adjusted EBITDA as earnings less interest, taxes (if any), depreciation and amortization and further adjusted to exclude stock compensation expense and the unrealized gain (loss) on the change in fair value of derivative liabilities (mark to market adjustment for warrants). This financial measure excludes the impact of certain items and, therefore, has not been calculated in accordance with GAAP. The Company’s method of calculating Adjusted EBITDA, however, may differ from methods used by other companies, and, as a result, Adjusted EBITDA measures disclosed herein may not be comparable to other similarly titled measures used by other companies. The Company continues to provide information in accordance with GAAP. However, with the adoption of ASC 815-40 and the non-cash variable nature of stock compensation expense and their very substantial impact on the overall reported net income/loss, the Company believes it is also helpful for investors to receive additional information relating more specifically to the Company's operating results. Accordingly, the Company has presented Adjusted EBITDA which excludes the non-cash effects of ASC 815-40 and ASC 718 on its financial results. Management uses Adjusted EBITDA (a) to evaluate the Company's financial performance, (b) to set internal spending budgets, and (c) to measure operational profitability. In addition, investors have requested these non-GAAP financial measures as a means of providing consistent and comparable information with past reports of financial results. Pursuant to the requirements of Regulation G, the Company has provided a reconciliation of Adjusted EBITDA to the most directly comparable GAAP financial measure, net (loss)/income.

 

About VirtualScopics, Inc.

VirtualScopics, Inc. is a leading provider of quantitative imaging solutions to accelerate drug and medical device development in addition to improving patient care. VirtualScopics has developed a robust software platform for analysis and modeling of both structural and functional medical images. In combination with VirtualScopics’ industry-leading experience and expertise in advanced imaging biomarker measurement, this platform provides a uniquely clear window into the biological activity of drugs and devices in clinical trial patients, allowing sponsors to make better decisions faster. For more information about VirtualScopics, visit www.virtualscopics.com.

 

####

 

Forward-Looking Statements

The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbors created thereby. These forward-looking statements include, but are not limited to, statements regarding the expected benefits of the Company’s investment in infrastructure and efforts to maximize new project bookings, new customer contract signings and awards and/or statements preceded by, followed by or that include the words “believes,” “could,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “projects,” “seeks,” or similar expressions. Forward-looking statements deal with the Company’s current plans, intentions, beliefs and expectations. Investors are cautioned that all forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements.  Many of these risks and uncertainties are discussed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2011 filed with the Securities and Exchange Commission (the “SEC”), and in any subsequent reports filed with the SEC, all of which are available at the SEC’s website at www.sec.gov. These include without limitation: the risk of cancellation or delay of customer contracts or specifically as it relates to contact awards; the risk that they may not get signed; and, the risk that the Company may not receive contract awards which it has sought.  Other risks include the company’s dependence on its largest customers and risks of contract performance, protection of our intellectual property and the risks of infringement of the intellectual property rights of others. All forward-looking statements speak only as of the date of this press release and the Company undertakes no obligation to update such forward-looking statements.

 

-2-
 

 

-Financial tables to follow-

 

CONTACT: Investor Relations: Company Contact:
Tim Ryan Molly Henderson
  The Shoreham Group Chief Business and Financial Officer, Sr. Vice President
  80 Eighth Ave, Ste 1107 500 Linden Oaks
  New York, NY 10011 Rochester, New York 14625
  +1 212 242.7777 Direct +1 585 249.6231
  tryan@shorehamgroupllc.com  

 

-3-
 

 

VirtualScopics, Inc. and Subsidiary

Condensed Consolidated Statements of Operations

(unaudited)

 

   For the Three Months Ended September 30,   For the Nine Months Ended September 30, 
   2012   2011   2012   2011 
                 
Revenues  $3,095,080   $3,047,704   $9,487,055   $9,973,568 
Reimbursement revenues   233,137    221,103    879,181    807,142 
Total revenues   3,328,217    3,268,807    10,366,236    10,780,710 
                     
Cost of revenues   1,633,024    1,551,078    5,270,148    5,056,183 
Cost of reimbursement revenues   233,137    221,103    879,181    807,142 
Total cost of services   1,866,161    1,772,181    6,149,329    5,863,325 
Gross profit   1,462,056    1,496,626    4,216,907    4,917,385 
                     
Operating expenses                    
Research and development   397,803    320,024    1,111,967    984,730 
Sales and marketing   312,140    254,696    954,605    864,409 
General and administrative   578,107    594,683    1,848,007    1,882,865 
Stock-based compensation expense   125,906    194,050    421,092    631,984 
Depreciation and amortization   101,393    113,614    320,003    364,062 
Total operating expenses   1,515,349    1,477,067    4,655,674    4,728,050 
Operating (loss) income   (53,293)   19,559    (438,767)   189,335 
                     
Other income (expense)                    
Interest income   1,044    1,671    2,174    15,903 
Other expense   (7,206)   (6,724)   (12,920)   (24,665)
Unrealized (loss) gain on change in   fair value of derivative liabilities   (19,794)   548,420    (306,247)   509,621 
Total other (expense) income   (25,956)   543,367    (316,993)   500,859 
Net (loss) income   (79,249)   562,926    (755,760)   690,194 
                     
Preferred stock deemed dividend   -    -    1,806,919    - 
Preferred stock dividends   42,000    12,000    95,333    36,989 
                     
Net (loss) income available to common stockholders  $(121,249)  $550,926   $(2,658,012)  $653,205 
                     
Weighted average number of common shares outstanding                    
basic   29,747,262    29,329,816    29,608,684    28,809,385 
diluted   29,747,762    32,524,658    29,608,684    33,471,117 
                     
Basic and diluted (loss) earnings per common share  $0.00   $0.02   $(0.09)  $0.02 

 

* Cost of revenues includes non-cash stock-based compensation expense of $18,039 and $14,446 for the three months ended
  September 30, 2012 and 2011, respectively and $44,796 and $38,465 for the nine months ended September 30, 2012 and 2011, respectively.

 

-4-
 

 

VirtualScopics, Inc. and Subsidiary

Condensed Consolidated Balance Sheets

 

   September 30,   December 31, 
   2012   2011 
   (unaudited)     
Assets          
           
Current assets          
Cash  $8,060,832   $5,737,009 
Accounts receivable, net   2,728,663    2,435,496 
Prepaid expenses and other current assets   406,438    361,376 
Total current assets   11,195,933    8,533,881 
Patents, net   1,497,922    1,582,938 
Property and equipment, net   418,976    514,230 
Other assets   10,856    27,140 
Total assets  $13,123,687   $10,658,189 
           
Liabilities and Stockholders' Equity          
           
Current liabilities          
Accounts payable and accrued expenses  $913,262   $843,275 
Accrued payroll   474,099    759,470 
Unearned revenue   240,266    421,486 
Derivative liabilities   57,610    156,596 
Total current liabilities   1,685,237    2,180,827 
           
Commitments and Contingencies   -    - 
           
Stockholders' Equity          
Convertible preferred stock, $0.001 par value; 15,000,000 shares authorized;          
Series A 8,400 shares authorized; issued and outstanding, 2,190 at September 30, 2012 and December 31, 2011; liquidation preference $1,000 per share   2    2 
Series B 6,000 shares authorized; issued and outstanding, 600 at September 30, 2012 and December 31, 2011; liquidation preference $1,000 per share   1    1 
Series C-1 3,000 shares authorized; issued and outstanding, 3,000 and 0 shares at September 30, 2012 and December 31, 2011, respectively; liquidation preference $1,000 per share   3    - 
Series C-2 3,000 shares authorized; issued and outstanding, 0 shares at September 30, 2012 and December 31, 2011; liquidation preference $1,000 per share   -    - 
Common Stock, $0.001 par value; 85,000,000 shares authorized; issued and outstanding, 29,747,762 and 29,370,687 shares at September 30, 2012 and December 31, 2011, respectively   29,748    29,371 
Additional paid-in capital   21,599,404    17,882,936 
Accumulated deficit   (10,190,708)   (9,434,948)
Total stockholders' equity   11,438,450    8,477,362 
Total liabilities and stockholders' equity  $13,123,687   $10,658,189 

 

-5-
 

  

   Three Months Ended   Three Months Ended 
   September 30, 2012   September 30, 2011 
Adjusted EBITDA (non-GAAP measurement):  (unaudited)   (unaudited) 
         
Net (loss) income  $(79,249)  $562,926 
Interest income and other expenses   6,162    5,053 
Depreciation and amortization   101,393    113,614 
Stock-based compensation expense   143,945    208,496 
Unrealized loss (gain) on change in fair value of derivative liabilities   19,794    (548,420)
Adjusted EBITDA  $192,045   $341,669 
Basic and diluted Adjusted EBITDA per common share, non-GAAP  $0.01   $0.01 

 

   Nine Months Ended   Nine Months Ended 
   September 30, 2012   September 30, 2011 
Adjusted EBITDA (non-GAAP measurement):  (unaudited)   (unaudited) 
         
Net (loss) income  $(755,760)  $690,194 
Interest income and other expenses   10,746    8,762 
Depreciation and amortization   320,003    364,062 
Stock-based compensation expense   465,888    670,449 
Unrealized loss (gain) on change in fair value of derivative liabilities   306,247    (509,621)
Adjusted EBITDA  $347,124   $1,223,846 
Basic and diluted Adjusted EBITDA per common share, non-GAAP  $0.01   $0.04 

 

-6-